Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Public ClinicalTrials.gov record NCT00790842. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. Lenalidomide and dexamethasone may have different effects in patients who have changes in their kidney function.
Study identification
- NCT ID
- NCT00790842
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2009 (Actual)
- Primary completion
- Sep 30, 2017 (Actual)
- Completion
- Mar 8, 2018 (Actual)
- Last update posted
- Oct 24, 2018
2009 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | Arizona | 85259-5499 | — |
| Emory University Winship Cancer | Atlanta | Georgia | 30322 | — |
| University of IL at Chicago | Chicago | Illinois | 60612 | — |
| McFarland Clinic | Ames | Iowa | 50010 | — |
| Siouxland Hematology Oncology Associates | Sioux City | Iowa | 51101 | — |
| Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor | Ann Arbor | Michigan | 48106-0955 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Metro MN CCOP | Saint Louis Park | Minnesota | 55416 | — |
| Missouri Valley Cancer Consortium | Omaha | Nebraska | 68106 | — |
| Kinston Medical Specialists | Kinston | North Carolina | 28501 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104-4283 | — |
| Reading Hospital and Medical Center | West Reading | Pennsylvania | 19611 | — |
| WVU Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
| Gundersen Lutheran | La Crosse | Wisconsin | 54601 | — |
| Waukesha Memorial Hospital (ProHealth Care) | Waukesha | Wisconsin | 53188 | — |
| Aurora Cancer Center | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00790842, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2018 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00790842 live on ClinicalTrials.gov.